National investment loss lawyers KlaymanToskes is investigating Aegis Capital and financial advisors who unsuitably recommended investments in Aegis’ Special Situations Funds to their customers. Our law firm believes many investors may have been misled regarding the risks and liquidity issues associated with Aegis’ private placement offerings.
If your financial advisor recommended unsuitable investments in Aegis Capital funds based on your investment profile, or disregarded your risk-tolerance when making investment recommendations, you may be entitled to a financial recovery through FINRA arbitration.
If you suffered losses in Aegis Special Situations Funds, or any other Aegis Capital investments due to unsuitable recommendations by your financial advisor, contact securities attorney Steven D. Toskes to discuss your recovery options at (888) 997-9956 or investigations@klaymantoskes.com for a free and confidential consultation. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.
KlaymanToskes is investigating the following Aegis private placement offerings:
Aegis Special Situation Fund | Total Amount Raised |
| Aegis Special Situations QP Fund LLC – Series MedTech IV (Acquyre Biosciences. Inc. | $4.8 million |
| Aegis Special Situations Fund, LLC- Series Medtech V (Cordio Medical Ltd.) | $11.6 million |
| Aegis Special Situations Fund, LLC- Series Medtech VI (Pristine Surgical LLC) | $11.1 million |
| Aegis Special Situations QP Fund, LLC- Series Medtech VI (Pristine Surgical) | $4.2 million |
| Aegis Special Situations Fund, LLC- Series Medtech VII (Orchestra BioMed Inc) | $4.3 million |
| Aegis Special Situations Fund, LLC- Series Medtech VIII (GT Metabolic Solutions, Inc.) | $4.2 million |
| Aegis Special Situations QP Fund, LLC- Series Medtech VIII (GT Metabolic Solutions Inc.) | $2.3 million |
| Aegis Special Situations Fund, LLC- Series Aerospace III (Axiom Space) | $10.9 million |
| Aegis Special Situations Fund, LLC- Series Medtech IX (Diasome Inc.) | $8.7 million |
| Aegis Special Situations Fund, LLC- Series Medtech X (Momentis Surgical Ltd. (f/k/a Memic Innovative Surgery Ltd.)) | $5.9 million |
| Aegis Special Situations Fund, LLC- Series Agritech II (Indigo Ag, Inc.) | $9.6 million |
| Aegis Special Situations QP Fund, LLC- Series Agritech II (Indigo Ag, Inc.) | $5.1 million |
| Aegis Special Situations Fund, LLC- Series Fintech I (Chime) | $11.5 million |
| Aegis Special Situations Fund, LLC- Series Aerospace II (World View Enterprises, Inc.) | $4.4 million |
| Aegis Special Situations Fund, LLC- Series Medtech IV (Aquyre Biosciences, Inc.) | $13.4 million |
| Aegis Special Situations Fund, LLC- Series Big Data II (ThoughtSpot, Inc.) | $14.1 million |
| Aegis Special Situations Fund, LLC- Series Medtech V (Cordio Medical, Ltd.) | $10.3 million |
| Aegis Special Situations Fund, LLC- Series Medtech VI (Pristine Surgical, LLC) | $5.6 million |
| Aegis Special Situations Fund, LLC- Series HealthTech I (ZocDoc, Inc.) | $11.8 million |
| Aegis Special Situations Fund, LLC- Series Fintech III (Kraken) | $11.5 million |
| Aegis Special Situations Fund, LLC- Series Medtech I (DermaSensor, Inc.) | $4.9 million |
| Aegis Special Situations Fund, LLC- Series Digital Freight Network I (Convoy) | $10.6 million |
| Aegis Special Situations Fund, LLC- Series Education II (Coursera) | $5.2 million |
| Aegis Special Situations Fund, LLC- Series Medtech II (Momentis Surgical Ltd. (f/k/a Memic Innovative Surgery Ltd.)) | $17.9 million |
| Aegis Special Situations Fund, LLC- Series Medtech III (QinFlow) | $7.8 million |
| Aegis Special Situations Fund, LLC- Series Aerospace I (SpaceX) | $5.2 million |
| Aegis Special Situations QP Fund, LLC- Series Aerospace I (SpaceX) | $2.2 million |
| Aegis Special Situations Fund, LLC- Series Big Data I (Palantir Technologies) | $9.4 million |
| Aegis Special Situations Fund, LLC- Series Plant Protein I (Impossible Foods Inc.) | $5.2 million |
| Aegis Special Situations QP Fund, LLC- Series Plant Protein I (Impossible Foods Inc.) | $9.7 million |
| Aegis Special Situations Fund, LLC- Series Hospitality I (Airbnb, Inc.) | $2.4 million |
| Aegis Special Situations Fund, LLC- Series Agritech I (Hydrofarm Holdings Group, Inc.) | $4.9 million |
| Aegis Special Situations QP Fund, LLC- Series Agritech I (Hydrofarm Holdings Group, Inc.) | $5.7 million |
| Aegis Special Situations Fund, LLC- Series Fantasy Sports I (DraftKings Inc.) | $3.6 million |
| Aegis Special Situations Fund LLC, Series Rideshare I (DiDi Chuxing Technology Co.) | $10.7 million |
| Aegis Special Situations Fund, LLC- Series Education I (Udacity, Inc.) | $3.5 million |
| Aegis Special Situations Fund, LLC- Series DNA I (23andMe) | $5.3 million |
| Aegis Special Situations QP Fund, LLC- Series Hospitality I (Airbnb, Inc.) | $8.1 million |
| Aegis Special Situations QP Fund, LLC- Series Rideshare I (DiDi Chuxing Technology Co.) | $5.8 million |
| Aegis Special Situations Fund II, LLC – Series Rideshare I (Lyft, Inc.) | $11.8 Million |
Aegis Capital Corp. has established a series of Special Situations Funds, continuing its pattern of offering high-risk investments. Aegis’ Special Situations private placement funds, which have collectively raised approximately $350 million, are structured to invest in mid- or late-stage pre-IPO technology and services companies.
The primary funds formed by Aegis under this series include the following:
The strategy behind Aegis’ Special Situations Funds is to purchase securities from issuer shareholders. This can be done directly from the shareholders or through direct private placement transactions. The term “pre-IPO” refers to investments in securities of companies that have not yet gone public, meaning they are not available on the public stock exchange.
Aegis Capital’s Special Situations Funds are high-risk private placement investments. Private placements or “Reg D” offerings can be highly volatile investments, as they are early-stage companies with limited information and are exempt from registering with the Securities and Exchange Commission (“SEC”). Consequently, these companies are not required to disclose financial details or the specific risks associated with their investments, increasing the overall risk for investors.
The brokers and financial advisors responsible for selling Aegis’ Special Situations Funds may be held responsible for any financial losses sustained by investors. Brokerage firms and financial advisors must consider their client’s risk tolerance prior to making recommendations, and cannot overconcentrate their customers’ accounts in any one investment product or market sector.
KlaymanToskes is a leading national securities fraud law firm that represents the interests of investors throughout the world who have suffered losses due to broker misconduct, investment fraud, and securities violations.
The article linked below contains important information relating to KlaymanToskes’ investigations of Aegis’ Special Situations Funds:
If you suffered losses in Aegis’ Special Situations Funds, or any other investments, contact securities attorney Steven D. Toskes to discuss your recovery options at (888) 997-9956 or fill out a short contact form for a free and confidential consultation.
The firm has helped recover over $600 million for investors (exclusive of attorneys fees and costs), and can help you determine if your loss is due to financial advisor misconduct, unsuitable investment advice, and/or other securities violations.
Potential conflicts of interest may arise when issuers incentivize brokers/investment advisors with substantial commissions to promote their financial products. A problem often associated with private placement investment recommendations is the high sales commissions brokers typically earn for selling these investments. A representative that recommends investments for the purpose of being compensated through increased commissions, and enriches themselves rather than benefiting the client, is violating securities laws.
To recover investment losses, you do not go through the traditional court system with a lawsuit. The only remedy is through a FINRA arbitration, a specific process designed for these types of disputes. This process involves presenting your case to a panel set by the Financial Industry Regulatory Authority (FINRA), not a courtroom. This approach is streamlined and focused on investment disputes, making it a suitable and effective way for investors to seek compensation for losses caused by financial advisors or brokerage firms.
FINRA (the Financial Industry Regulatory Authority) is a self-regulatory organization that oversees brokers and brokerages. In the event of a dispute between an investor and their financial advisor, investors can choose to file a FINRA arbitration claim. FINRA is overseen by the Securities and Exchange Commission (“SEC”).
The arbitration process is designed to be much faster than the court system and allows both parties to present their case before a panel of arbitrators. The arbitrators will then decide how to resolve the dispute, including ordering the advisor to pay damages for any losses suffered by the investor.
If you suffered losses in Aegis’ Special Situations Funds or any other investments, contact attorney Steven D. Toskes, at 888-997-9956 or by email at investigations@klaymantoskes.com to discuss recovery options. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.
As an investor, there are signs that you should look out for if you believe you have a claim against your broker/advisor for unsuitable investment recommendations in Vista Funds. These signs could potentially indicate misconduct, negligence, or investment fraud. Investors are encouraged to contact our firm immediately if you have experienced any of the following:
Some investors have close relationships with their brokers due to the time and trust built over the course of their investment relationship. However, it is crucial to remember that financial decisions should be based on careful analysis and due diligence rather than solely relying on personal relationships.
Engaging the services of an experienced securities attorney to evaluate your specific circumstances is strongly advised. At KlaymanToskes, our team of experienced securities attorneys has a deep understanding of this complex area of law, allowing us to provide invaluable insight and tailored guidance that directly addresses your individual needs.
If you purchased unsuitable Aegis Capital Special Situations Funds, or any other unsuitable investments through your financial advisor/brokerage firm, and suffered significant losses, contact KlaymanToskes at 888-997-9956 or fill out a short contact form for a free and confidential consultation. We do not collect attorney’s fees unless we are able to obtain a financial recovery for you.